Domenica Lorusso, MD, PhD, on Cervical Cancer: Results From a Trial on Treatment Regimens
2017 ESMO Congress
Domenica Lorusso, MD, PhD, of the National Cancer Institute of Milan, discusses neoadjuvant chemotherapy followed by surgery vs concurrent cisplatin and radiation therapy in patients with stage IB2 to IIB squamous carcinoma of the cervix (Abstract 928O_PR).
Simone Koole, MD (and a PhD candidate), of the Netherlands Cancer Institute, discusses phase III findings on health-related quality of life after hyperthermic intraperitoneal chemotherapy for stage III ovarian cancer.
Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metastatic renal cell carcinoma (Abstract 1137O).
Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negative breast cancer (Abstract LBA14).
Sandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, summarizes findings from the ICON8 study on dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma treatment; the ARIEL3 study on rucaparib vs placebo in recurrent ovarian carcinoma; and the ENGOT-OV16/NOVA on quality of life in patients with recurrent ovarian cancer treated with niraparib (Abstracts 929O, LBA40, 930O).
David A. Tuveson, MD, PhD, of Cold Spring Harbor Laboratory, discusses the most lethal of cancers. Although treatments are improving, the challenges are great, including early detection of this malignancy, which metastasizes early in its development.